Riskpilot← Back to searchSign inGet full accessTricolor Pharma AB
ABIn liquidationOrg 5569722688Mässans Gata 18 5trWholesale of pharmaceutical and medical goods · NACE 4646Est. 20140 employees
Revenue 2024
SEK 1,2M
-15% vs 2023
EBITDA margin
41.4%
+195% vs 2023
Equity ratio
58.8%
Financial strength
Net profit 2024
SEK 456K
+178% vs 2023
| Revenue | SEK 1,2M | -15% |
| EBITDA | SEK 483K | +195% |
| Net profit | SEK 456K | +178% |
| Total assets | SEK 862K | -8% |
| Equity | SEK 507K | +120% |
| Employees | 0 | — |
Legal name
Tricolor Pharma AB
Org number
5569722688
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
21 maj 2014
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget ska bedriva partihandel inom medicinsk utrustning & apoteksvaror samt därmed förenlig verksamhet.
Address
Mässans Gata 18 5tr
Email
lena@redovisninglmc.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 1 751 | 1 608 | 746 | 2 171 | 3 640 | 1 367 | 1 166 |
| Staff expenses | — | — | — | — | — | — | — | — | — | −3 |
| EBITDA | −74 | −431 | −246 | 196 | 280 | 49 | 356 | 147 | 164 | 483 |
| Depreciation & amort. | −0 | −33 | −0 | −144 | −144 | −144 | −111 | −0 | −0 | — |
| EBIT | −74 | −464 | −246 | 52 | 136 | −95 | 245 | 147 | 164 | 483 |
| Net financials | −25 | −36 | −44 | −44 | −18 | −22 | −12 | −14 | — | −0 |
| Profit before tax | −99 | −500 | −290 | 8 | 118 | −117 | 233 | 133 | 164 | 483 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −27 |
| Net profit | −99 | −500 | −290 | 8 | 118 | −117 | 233 | 133 | 164 | 456 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 499 | 1 598 | 1 032 | 1 243 | 1 103 | 392 | 449 | 1 406 | 941 | 862 |
| Equity | 30 | 130 | 90 | 98 | 216 | 99 | 332 | 465 | 230 | 507 |
| Long-term debt | 344 | 1 055 | 759 | 389 | 206 | 200 | 0 | 0 | 0 | — |
| Short-term debt | 125 | 413 | 183 | 756 | 680 | 93 | 117 | 941 | 711 | 355 |
| Total debt | 469 | 1 468 | 942 | 1 145 | 886 | 293 | 117 | 941 | 711 | 355 |
EBITDA margin
41.4%
This company
15.8%
Market median
+162% vs market
20152024
Equity ratio
58.8%
This company
38.2%
Market median
+54% vs market
20152024
Return on equity
90.0%
This company
18.4%
Market median
+389% vs market
20152024
Net profit margin
39.1%
This company
8.1%
Market median
+383% vs market
20152024
Asset turnover
1.35×
This company
1.12×
Market median
+21% vs market
20152024
Debt / equity
0.70×
This company
0.62×
Market median
+13% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
UA | Audit | 2022 | — | — |
KJ Chief Auditor | Chief Auditor | 2024 | — | — |
LM Liquidator | Liquidator | 2026 | — | — |
GT Audit | Audit | 2024 | — | — |
HB Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Deputy Board Member | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Tricolor Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ulf Anders Göransson Borén | Audit | 0 companies |
| Karin Johanna Gustafsson | Chief Auditor | 0 companies |
| Lena Marie Carlberg | Liquidator | 0 companies |
| Gabriel Topuz | Audit | 0 companies |
| Helena Birgitta Törnell | Chief Executive Officer | 0 companies |
| Per Åke Anders Åkerman | Chairman | 0 companies |
| Jennie Magdalena Berglund | Deputy Board Member | 0 companies |